Oxford Biomedica (LON:OXB) Shares Pass Below Two Hundred Day Moving Average – Here’s Why

Shares of Oxford Biomedica plc (LON:OXB) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 663.28 and traded as low as GBX 586. Oxford Biomedica shares last traded at GBX 606.25, with a volume of 425,721 shares trading hands.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on OXB. Royal Bank Of Canada dropped their target price on Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating for the company in a report on Wednesday, June 24th. Jefferies Financial Group restated a “buy” rating and set a GBX 8.27 price target on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Oxford Biomedica has a consensus rating of “Moderate Buy” and an average price target of GBX 600.04.

Oxford Biomedica Stock Up 2.2%

The company has a 50-day simple moving average of GBX 614.11 and a 200-day simple moving average of GBX 663.28. The firm has a market cap of £754.33 million, a PE ratio of -23.15 and a beta of 1.12. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.